Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Newly Diagnosed, Previously Untreated Multiple Myeloma”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Study completedNCT00089167
What this trial is testing

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Study completedNCT02541383
What this trial is testing

Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Intergroupe Francophone du Myelome 1,085
Testing effectiveness (Phase 2)Study completedNCT01029054
What this trial is testing

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Michigan Rogel Cancer Center 53
Testing effectiveness (Phase 2)Study completedNCT00531453
What this trial is testing

Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 98
Large-scale testing (Phase 3)Ended earlyNCT01891643
What this trial is testing

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Who this might be right for
Newly Diagnosed, Previously Untreated Multiple Myeloma
Bristol-Myers Squibb 23
Testing effectiveness (Phase 2)Study completedNCT01698801
What this trial is testing

Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 26
Testing effectiveness (Phase 2)UnknownNCT00438841
What this trial is testing

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Fred Hutchinson Cancer Center 43
Large-scale testing (Phase 3)Study completedNCT00057564
What this trial is testing

Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene Corporation 470
Testing effectiveness (Phase 2)Study completedNCT01531998
What this trial is testing

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 14
Large-scale testing (Phase 3)Study completedNCT03993912
What this trial is testing

Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

Who this might be right for
Multiple Myeloma
University Hospital, Lille 294
Large-scale testing (Phase 3)Study completedNCT00934154
What this trial is testing

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Cigdem Sahinbas YILMAZ 122
Large-scale testing (Phase 3)UnknownNCT01685814
What this trial is testing

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Who this might be right for
Previously Untreated Symptomatic Multiple Myeloma
Wuerzburg University Hospital 406
Testing effectiveness (Phase 2)UnknownNCT01114048
What this trial is testing

Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Chonnam National University Hospital 78
Testing effectiveness (Phase 2)Study completedNCT02272803
What this trial is testing

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 82
Large-scale testing (Phase 3)Study completedNCT01335399
What this trial is testing

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 748
Testing effectiveness (Phase 2)Looking for participantsNCT05828511
What this trial is testing

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 149
Large-scale testing (Phase 3)Study completedNCT00689936
What this trial is testing

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 1,623
Early research (Phase 1)Ended earlyNCT04892264
What this trial is testing

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Who this might be right for
Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 5